...
首页> 外文期刊>The Indian journal of medical research >Prevalence of multidrug-resistant tuberculosis among newly diagnosed cases of sputum-positive pulmonary tuberculosis
【24h】

Prevalence of multidrug-resistant tuberculosis among newly diagnosed cases of sputum-positive pulmonary tuberculosis

机译:新诊断的痰阳性肺结核病例中多药耐药结核的患病率

获取原文
           

摘要

Background & objectives : The prevalence of multidrug-resistant tuberculosis (MDR-TB) is increasing throughout the world. Although previous treatment for TB is the most important risk factor for development of MDR-TB, treatment-naοve patients are also at risk due to either spontaneous mutations or transmission of drug-resistant strains. We sought to ascertain the prevalence of MDR-TB among new cases of sputum-positive pulmonary TB. Methods: This was a prospective, observational study involving newly diagnosed cases of sputum-positive pulmonary tuberculosis diagnosed between 2008 and 2009 carried out in New Delhi, India. All sputum-positive TB cases were subjected to mycobacterial culture and first-line drug-susceptibility testing (DST). MDR-TB was defined as TB caused by bacilli showing resistance to at least isoniazid and rifampicin. Results: A total of 218 cases of sputum-positive pulmonary tuberculosis were enrolled between 2008 and 2009. Of these, 41 cases had negative mycobacterial cultures and DST was carried out in 177 cases. The mean age of the patients was 27.8 ± 10.2 yr; 59 patients (27%) were female. All patients tested negative for HIV infection. Out of 177 cases, two cases of MDR-TB were detected. Thus, the prevalence of MDR-TB among newly diagnosed pulmonary tuberculosis patients was 1.1 per cent. Interpretation & conclusion s: MDR-TB prevalence is low among new cases of sputum-positive pulmonary TB treated at primary care level in Delhi. Nation-wide and State-wide representative data on prevalence of MDR-TB are lacking. Efforts should be directed towards continued surveillance for MDR-TB among newly diagnosed TB cases.
机译:背景与目标:耐多药结核病(MDR-TB)的流行在世界范围内不断增加。尽管先前对结核病的治疗是导致耐多药结核病发展的最重要风险因素,但由于自发突变或耐药菌株的传播,未经治疗的患者也面临风险。我们试图确定在痰阳性肺结核新病例中的耐多药结核病患病率。方法:这是一项前瞻性观察性研究,涉及在印度新德里进行的2008年至2009年之间确诊的痰阳性的肺结核病例。所有痰阳性结核病例均接受了分枝杆菌培养和一线药物敏感性试验(DST)。 MDR-TB被定义为由细菌引起的结核病,至少对异烟肼和利福平具有抗药性。结果:2008年至2009年共纳入218例痰阳性的肺结核病例。其中41例分枝杆菌培养阴性,177例进行了DST。患者的平均年龄为27.8±10.2岁; 59例患者(占27%)为女性。所有患者的HIV感染测试均为阴性。在177例中,发现了2例耐多药结核病。因此,在新诊断的肺结核患者中,耐多药结核病的患病率为1.1%。解释与结论:在德里,在初级保健机构就诊的痰阳性肺结核新病例中,耐多药结核病患病率较低。缺乏关于耐多药结核病流行的全国性和全国性代表性数据。应努力继续对新诊断的结核病病例进行耐多药结核病的监测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号